Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

15

TAGS:

description

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power. PRIMO: Observational Study in 7924 Patients. Genetics: PCSK9. PCSK9 Monoclonal Antibody vs Placebo on LDL-C Levels. Dosing and Administration. LAPLACE-TIMI 57: AMG 145 Q2W Dose Response -- Change in LDL-C From Baseline. - PowerPoint PPT Presentation

Transcript of Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

Page 1: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 2: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 3: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 4: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 5: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 6: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 7: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 8: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 9: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 10: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 11: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 12: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 13: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 14: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 15: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

Update on PCSK9 Inhibitors

Update on PCSK9 Inhibitors

PowerPoint Presentation€¦ · Angina pectoris Mutations in LDL receptor, apolipoprotein B or PCSK9 . 200 E 150 100 Homozygous FH Heterozygous FH Female sex Smoking Hypertension

PowerPoint Presentation€¦ · Angina pectoris Mutations in LDL receptor, apolipoprotein B or PCSK9 . 200 E 150 100 Homozygous FH Heterozygous FH Female sex Smoking Hypertension

PCSK9 Dominant Negative Mutant Results in Increased LDL ... · was determined in 10 normolipemic fasted controls (5 women and 5 men, 25.7 4.7 year old, total cholesterol: 173 3 mg/dL,

PCSK9 Dominant Negative Mutant Results in Increased LDL ... · was determined in 10 normolipemic fasted controls (5 women and 5 men, 25.7 4.7 year old, total cholesterol: 173 3 mg/dL,

The Value of PCSK9 Inhibitors: A Matter of Perspective€¦ · Autosomal dominant inheritance pattern 2. Most mutations occur in the LDL-receptor gene—on chromosome 19 3. Mutations

The Value of PCSK9 Inhibitors: A Matter of Perspective€¦ · Autosomal dominant inheritance pattern 2. Most mutations occur in the LDL-receptor gene—on chromosome 19 3. Mutations

PCSK9 Dominant Negative Mutant Results in Increased LDL ... · CEA, Gif sur Yvette, France; APHP, Hoˆpital Saint-Antoine, Biochimie B, Laboratoire de Re´fe´rence pour le Diagnostic

PCSK9 Dominant Negative Mutant Results in Increased LDL ... · CEA, Gif sur Yvette, France; APHP, Hoˆpital Saint-Antoine, Biochimie B, Laboratoire de Re´fe´rence pour le Diagnostic

The Role of PCSK9 in the Regulation of LDL Cholesterol · 2020. 7. 10. · surface, PCSK9 reduces the concentration of LDLRs on the surface of the hepatocytes, resulting in a lower

The Role of PCSK9 in the Regulation of LDL Cholesterol · 2020. 7. 10. · surface, PCSK9 reduces the concentration of LDLRs on the surface of the hepatocytes, resulting in a lower

Engineered Red Blood Cells Carrying PCSK9 Inhibitors Persistently Lower LDL … · 2020. 11. 2. · degradation by PCSK9 and thus lower LDL levels (for review see reference [9]).

Engineered Red Blood Cells Carrying PCSK9 Inhibitors Persistently Lower LDL … · 2020. 11. 2. · degradation by PCSK9 and thus lower LDL levels (for review see reference [9]).

PCSK9 Inhibitors, The Most Significant Advance in Lipid ...Wilson PCSK9 Inhibitors 25 of the first PCSK9 inhibitors in 2015, Repatha (evolocumab) and Praluent (alirocumab) both indicated

PCSK9 Inhibitors, The Most Significant Advance in Lipid ...Wilson PCSK9 Inhibitors 25 of the first PCSK9 inhibitors in 2015, Repatha (evolocumab) and Praluent (alirocumab) both indicated

IR Conference Call on PCSK9 - Biotech Due Diligence...Decreasing CV Risk 8 LDL-C Guidelines Have Evolved to More Rigorous Goals These guidelines have identified people with documented

IR Conference Call on PCSK9 - Biotech Due Diligence...Decreasing CV Risk 8 LDL-C Guidelines Have Evolved to More Rigorous Goals These guidelines have identified people with documented

Genetic Variants of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Implications for Low-Density Lipoprotein Cholesterol (LDL-C) © 2014 Amgen Inc.

Genetic Variants of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Implications for Low-Density Lipoprotein Cholesterol (LDL-C) © 2014 Amgen Inc.

The Role of PCSK9 in the Regulation of LDL Cholesterol · PCSK9 function, which leads to decreased LDLR recycling to the cell surface.7,9 • This results in an autosomal-dominant

The Role of PCSK9 in the Regulation of LDL Cholesterol · PCSK9 function, which leads to decreased LDLR recycling to the cell surface.7,9 • This results in an autosomal-dominant

THERAPEUTICS A tale of two drugs - media.nature.com · cholesterol by liver cells, such that lowering PCSK9 expression reduces LDL cholesterol levels in the blood (high LDL levels

THERAPEUTICS A tale of two drugs - media.nature.com · cholesterol by liver cells, such that lowering PCSK9 expression reduces LDL cholesterol levels in the blood (high LDL levels

Cardiovascular Franchise: Multiple Approaches to ...€¦ · Targeting PCSK9 for Lipid Management PCSK9 mRNA Reduction Correlates with LDL-C Lowering in Preclinical Studies PCSK9

Cardiovascular Franchise: Multiple Approaches to ...€¦ · Targeting PCSK9 for Lipid Management PCSK9 mRNA Reduction Correlates with LDL-C Lowering in Preclinical Studies PCSK9

Clinical Pharmacokinetics and Pharmacodynamics of ......PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kinetics as a result of binding to PCSK9. Elimination is predominantly

Clinical Pharmacokinetics and Pharmacodynamics of ......PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kinetics as a result of binding to PCSK9. Elimination is predominantly

Next generation LDL-C management with ALN-PCSsc, an ... · Next generation LDL-C management with ALN-PCSsc, an investigational PCSK9 synthesis ... efficacy and safety of its ... an

Next generation LDL-C management with ALN-PCSsc, an ... · Next generation LDL-C management with ALN-PCSsc, an investigational PCSK9 synthesis ... efficacy and safety of its ... an

PCSK9...Bryan Heart Fall Conference 2015 PCSK9 Inhibitors Current Status Title Microsoft PowerPoint - PCSK9.pptx Author tlw011 Created Date 9/2/2015 3:31:45 PM ...

PCSK9...Bryan Heart Fall Conference 2015 PCSK9 Inhibitors Current Status Title Microsoft PowerPoint - PCSK9.pptx Author tlw011 Created Date 9/2/2015 3:31:45 PM ...

New Horizons in Dyslipidemia Management in Primary … PCSK9 Activity Inhibits Intracellular Degradation of LDL-R Qian YW, et al. J Lipid Res. 2007;48:1488-1498; Horton JD, et al.

New Horizons in Dyslipidemia Management in Primary … PCSK9 Activity Inhibits Intracellular Degradation of LDL-R Qian YW, et al. J Lipid Res. 2007;48:1488-1498; Horton JD, et al.

PCSK9 Inhibitors - Impact on the Management of LDL ... · LDL Apheresis Currently, there are more than 400 patients in North America receiving LDL apheresis therapy at more than 40

PCSK9 Inhibitors - Impact on the Management of LDL ... · LDL Apheresis Currently, there are more than 400 patients in North America receiving LDL apheresis therapy at more than 40

NEW DRUGS IN CARDIOLOGY PCSK9 INHIBITORS · • Discovery reported in 2003 and 2004 • PCSK9 missense/LOF mutations- ARIC study • African Americans : 28% less LDL-C, 88% lower

NEW DRUGS IN CARDIOLOGY PCSK9 INHIBITORS · • Discovery reported in 2003 and 2004 • PCSK9 missense/LOF mutations- ARIC study • African Americans : 28% less LDL-C, 88% lower

PCSK9 Inhibitors PP

PCSK9 Inhibitors PP